These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24080810)

  • 1. Male incontinence: onabotulinum toxin A and sacral nerve stimulation.
    Rashid TG; Ockrim JL
    Curr Opin Urol; 2013 Nov; 23(6):545-51. PubMed ID: 24080810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of electrical stimulation techniques in the management of the male patient with urgency incontinence.
    Johnsen NV; Osborn DJ; Dmochowski RR
    Curr Opin Urol; 2014 Nov; 24(6):560-5. PubMed ID: 25144143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
    Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
    J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation and management of refractory neurogenic overactive bladder.
    Kurpad R; Kennelly MJ
    Curr Urol Rep; 2014 Oct; 15(10):444. PubMed ID: 25118853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
    Ellsworth P
    Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What to do if pills do not work for urge incontinence--still many questions and ambiguities].
    Koldewijn EL
    Ned Tijdschr Geneeskd; 2012; 156(33):A5099. PubMed ID: 22894810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
    Kantartzis K; Shepherd J
    Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update in the treatment of male urinary incontinence.
    Bing MT; Uhlman MA; Kreder KJ
    Curr Opin Urol; 2013 Nov; 23(6):540-4. PubMed ID: 23945475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
    Leong RK; De Wachter SG; van Kerrebroeck PE
    Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 18. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary incontinence in women.
    Wood LN; Anger JT
    BMJ; 2014 Sep; 349():g4531. PubMed ID: 25225003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the treatment of overactive bladder.
    Dmochowski RR; Gomelsky A
    Curr Opin Urol; 2011 Jul; 21(4):286-90. PubMed ID: 21499104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.